• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.
 
  • Détails
Titre

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Ophthalmology and Therapy  
Auteur(s)
Garweg, J.G.
Auteure/Auteur
Blum, C.A.
Auteure/Auteur
Copt, R.P.
Auteure/Auteur
Eandi, C.M.
Auteure/Auteur
Hatz, K.
Auteure/Auteur
Prünte, C.F.
Auteure/Auteur
Seelig, E.
Auteure/Auteur
Somfai, G.M.
Auteure/Auteur
Liens vers les personnes
Eandi, Chiara  
Liens vers les unités
Hôpital ophtalmique Jules Gonin  
Ophtalmologie  
ISSN
2193-8245
Statut éditorial
Publié
Date de publication
2023-04
Volume
12
Numéro
2
Première page
639
Dernière page/numéro d’article
655
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Anti-vascular endothelial growth factor (anti-VEGF) therapies have become the standard of care in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), resulting in a remarkable decrease in disease-related vision loss. However, the need for regular injections places a significant burden on patients, caregivers, and the healthcare system and improvements in vision may not be maintained long term. As a result of its drying potency and duration of action, brolucizumab, an intravitreal anti-VEGF therapy approved for the treatment of nAMD and DME, could decrease injection frequency for patients and provide an efficacious treatment; however, balancing its benefits and risks can be challenging. There have been reports of intraocular inflammation (IOI) in patients treated with brolucizumab, which, if left untreated, may result in severe vision loss. Recent evidence, however, indicates that early recognition of IOI and prompt and aggressive systemic corticosteroid treatment in response to posterior segment involvement can lead to favorable outcomes in these relatively rare but severe cases. A series of consensus meetings were conducted in 2022 between Swiss medical retina experts and diabetologists, discussing the current data for brolucizumab and exploring various challenges to its use, including the associated risk of IOI. The outcome is a collation of practical insights and guidance for ophthalmologists on the use of brolucizumab in patients with nAMD and DME, including patient selection and assessment, treatment regimen and monitoring, and the recognition and management of adverse events.
Sujets

Brolucizumab

Diabetic macular edem...

Intraocular inflammat...

Neovascular age-relat...

Retinal vascular occl...

Retinal vasculitis

Side effects

Steroid-induced diabe...

Treatment

PID Serval
serval:BIB_A8A163A2B7E5
DOI
10.1007/s40123-023-00647-7
PMID
36633780
WOS
000913486000001
Permalien
https://iris.unil.ch/handle/iris/185908
Open Access
Oui
Date de création
2023-01-23T10:37:43.428Z
Date de création dans IRIS
2025-05-21T01:24:48Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

36633780_BIB_A8A163A2B7E5.pdf

Version du manuscrit

published

Licence

https://creativecommons.org/licenses/by-nc/4.0

Taille

947.63 KB

Format

Adobe PDF

PID Serval

serval:BIB_A8A163A2B7E5.P002

URN

urn:nbn:ch:serval-BIB_A8A163A2B7E55

Somme de contrôle

(MD5):e77c6b4c486daad35d1b634ff939d00a

  • Copyright © 2024 UNIL
  • Informations légales